Company intelligence / Profile preview
NLS Pharmaceutics AG
Zurich, Zurich, Switzerlandnlspharma.com ↗
- Ownership
- Public · NLSP
- Employees
- ~45
- Development stage
- Other
01
Overview
NLS Pharmaceutics AG develops therapies targeting rare and complex central nervous system disorders. Its lead asset, Quilience® (mazindol extended-release), has advanced to Phase III trials for narcolepsy. The company’s pipeline includes additional small molecule candidates and a newly licensed dual orexin receptor agonist platform (“DOXA”), which targets both symptomatic relief and disease modification in sleep-wake and neurodegenerative disorders. Recent preclinical data are promising, especially regarding the novel mechanism involving both orexin receptors and cathepsins. The company recently announced plans to merge with Kadimastem Ltd., combining cell therapy expertise with its CNS drug portfolio.
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- Small molecules (e.g., Mazindol ER/Quilience, AEX series)Dual orexin receptor agonists
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Jazz PharmaceuticalsUniversity Hospital ZurichStanford University Sleep Research CenterExclusive global license from Aexon Labs Inc. for DOXA platform
Beyond the preview
Go deeper on NLS Pharmaceutics AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLS Pharmaceutics AG.